These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35258866)

  • 1. [From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors].
    Valdes-Socin H; Scheen AJ; Jouret F; Grosch S; Delanaye P
    Rev Med Liege; 2022 Mar; 77(3):175-180. PubMed ID: 35258866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Story of Serendipities: From Phlorizin to Gliflozins.
    Helvacı Ö; Helvacı B
    Exp Clin Transplant; 2023 Jun; 21(Suppl 2):105-108. PubMed ID: 37496357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
    Choi CI
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
    Pérez López G; González Albarrán O; Cano Megías M
    Nefrologia; 2010; 30(6):618-25. PubMed ID: 21113210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering.
    Jörgens V
    Acta Diabetol; 2019 Jan; 56(1):29-31. PubMed ID: 30099672
    [No Abstract]   [Full Text] [Related]  

  • 6. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
    Ghezzi C; Loo DDF; Wright EM
    Diabetologia; 2018 Oct; 61(10):2087-2097. PubMed ID: 30132032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of SGLT1 and SGLT2 inhibitors.
    Rieg T; Vallon V
    Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.
    Chan HW; Ashan B; Jayasekera P; Collier A; Ghosh S
    Diabetes Metab Syndr; 2012; 6(4):224-8. PubMed ID: 23199545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
    Santulli G; Varzideh F; Forzano I; Wilson S; Salemme L; de Donato A; Lombardi A; Rainone A; Nunziata L; Jankauskas SS; Tesorio T; Guerra G; Kansakar U; Mone P
    Hypertension; 2023 Sep; 80(9):1800-1809. PubMed ID: 37403685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status.
    Matthews J; Herat L; Schlaich MP; Matthews V
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SGLT2 inhibitors : on the borders of diabetology, cardiology, nephrology and… primary care].
    Scheen A; Lancellotti P; Delanaye P; Giet D
    Rev Med Liege; 2023 Sep; 78(9):476-483. PubMed ID: 37712156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Interventions of Novel SGLT2 Inhibitors Against Metabolic Disorders: Transforming the Association into Perspectives.
    Irshad K; Akash MSH; Rehman K; Sharif H
    Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2169-2180. PubMed ID: 34139987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitors race to enter type-2 diabetes market.
    Sheridan C
    Nat Biotechnol; 2012 Oct; 30(10):899-900. PubMed ID: 23051788
    [No Abstract]   [Full Text] [Related]  

  • 19. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
    Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
    Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.